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ABSTRACT
In vitro and in vivo studies suggest that IGF-1 has a role in erythropoiesis. There 
is evidence that the rs35767 C/T polymorphism near IGF1 is associated with plasma 
IGF-1 levels. We investigated the effect of this polymorphism on hemoglobin (Hb) 
concentration and anemia. The study group comprised 3286 adult Whites. The rs35767 
polymorphism was screened using a TaqMan allelic discrimination assay. The rs35767 
polymorphism was not associated with age, gender, BMI, waist circumference, 
smoking, blood pressure, plasma glucose, HbA1c, type 2 diabetes, HOMA-IR, hsCRP, 
eGFR, and lipid profile. Erythrocyte sedimentation rate (ESR), fibrinogen, and fasting 
insulin levels were significantly lower in TT genotype carriers compared with C allele 
carriers. Hb concentration was significantly higher in carriers of the TT genotype 
compared with C allele carriers, and a lower proportion of TT carriers had anemia. As 
compared with TT genotype carriers, those bearing the CC genotype had a 2.4-fold 
higher risk of anemia (OR 2.40, 95%CI 1.19-4.82), and those with the CT genotype 
had a 2.0-fold higher risk of anemia (OR 2.06, 95%CI 1.04-4.11). The association 
remained significant when fasting insulin, eGFR, smoking, diabetes, ACE inhibitors, 
sartans or diuretics treatments, use of metformin and pioglitazone were added to the 
model, but its independence was not retained after inclusion of fibrinogen and ESR 
values into the model. In conclusion, rs35767 TT allele carriers exhibited significantly 
higher concentrations of Hb, and lower risk of anemia compared with C allele carriers 
supporting the idea that IGF-1 plays a role in erythropoiesis homeostasis.
INTRODUCTION
Anemia is a recognized risk factor for cardiovascular 
morbidity and mortality. There is compelling evidence 
that anemia is a risk factor for adverse outcomes in a 
number of clinical conditions including aging, diabetes 
mellitus, acute coronary syndromes, heart failure, 
chronic kidney disease [1-11]. Anemia is a multifactorial 
condition and several determinants may contribute 
to its pathogenesis, including failure of appropriate 
erythropoietin (EPO) production or EPO resistance, 
damage to EPO-producing peri-tubular cells, decreased 
proliferative capacity of bone marrow stem cells, impaired 
renal function, myelodysplasia, testosterone deficiency, 
chronic inflammation, iron deficiency, use of angiotensin-
converting enzyme (ACE) inhibitors or angiotensin II 
receptor blockers (ARBs) affecting EPO production, use 
of metformin, causing malabsorption of vitamin B12, or 
pioglitazone. 
In the last years, several in vitro and in vivo 
evidences have suggested that insulin-like growth factor-1 
(IGF-1) may play an important role in erythropoiesis. 
Indeed, it has been demonstrated that IGF-1 promotes 
erythropoiesis in vitro stimulating the proliferation and 
differentiation of the late stage of primitive erythroid 
progenitor cells and/or early erythroid progenitor 
cells [12-16]. Observational studies carried out in pre-
pubertal or early pubertal boys [17], nondiabetic adults 
[18], older (aged >65years) [19], and elderly individuals 
(aged >70 years) [20] have consistently shown that 
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IGF-1 plasma levels associated with hemoglobin (Hb) 
concentration and anemia. Additionally, intervention 
studies have demonstrated that short-term treatment with 
recombinant human GH increased Hb in malnourished 
dialysis patients [21] and elderly patients [22]. Although 
these results suggest that IGF-1 may play an important 
role in regulating Hb levels under both physiological and 
pathological conditions, these associations may be non-
causal. Factors that affect IGF-1 levels such as obesity, 
diabetes mellitus, adverse socioeconomic circumstances, 
and various disease states may themselves influence Hb 
concentration. The conventional approach to resolve 
this issue is to statistically adjust for such confounding 
factors, but this approach may produce misleading 
results, given measurement error in the assessment of 
confounders or the presence of unmeasured covariates, 
both of which lead to inadequate statistical control and 
residual confounding. Further, because all the studies that 
have assessed the association between IGF-1 levels and 
Hb concentration in adult subjects have a cross-sectional 
design [18-20], reverse causality cannot be excluded. 
Thus, the association between IGF-1 genotype and anemia 
can give an unconfounded test of whether IGF-1 levels 
causally influence outcomes. In an attempt to clarify this 
issue, we took advantage of the opportunity to study the 
association of an IGF-1-raising polymorphism near IGF1 
(rs35767) [23-28]. Indeed, it has been repeatedly reported 
that carriers of the rs35767 T allele exhibit higher levels of 
circulating IGF-1 [23-28]. In this study, we evaluated the 
association of the functional polymorphism rs35767 near 
IGF1 with Hb concentration and anemia in a large cohort 
of well-characterized adult White Europeans. 
RESULTS
Clinical characteristics of the study group 
according to rs35767 genotype are presented in Table 
1. The association between the rs35767 polymorphism 
and clinical characteristics was analysed according 
to both additive and recessive genetic models (Table 
1). The rs35767 polymorphism did not show any 
significant association with age, gender, body mass 
index (BMI), waist circumference, smoking status (yes/
no), blood pressure, fasting plasma glucose, glycated 
Hb (HbA1c), diagnosis of type 2 diabetes, homeostasis 
model assessment index of insulin resistance (HOMA-
IR) index, high-sensitivity C-reactive protein (hsCRP), 
estimated glomerular filtration rate (eGFR), and lipids 
levels (Table 1). Fasting insulin levels were significantly 
lower in carriers of the TT genotype as compared with 
subjects carrying the C allele, consistent with the data of 
a large scale meta-analysis of genome-wide association 
studies of fasting insulin traits in nondiabetic individuals 
conducted by the Meta-Analyses of Glucose and Insulin-
related traits Consortium (MAGIC) [29]. Carriers of the 
TT genotype exhibited significantly lower levels of ESR 
and fibrinogen as compared with subjects carrying the C 
allele (Table 1). No differences between genotypes were 
observed with respect to anti-hypertensive treatments, 
and use of metformin or pioglitazone in diabetic 
patients. The association of the rs35767 polymorphism 
with haematological parameters is reported in Table 2. 
Hemoglobin (Hb) concentration was significantly higher 
in carriers of the TT genotype as compared with C allele 
carriers, after adjusting for age and gender, and a lower 
proportion of TT carriers had anemia. No differences 
between genotypes were observed in hematocrit, 
mean corpuscular volume (MCV), mean corpuscular 
hemoglobin (MCH), and serum iron values. To estimate 
the independent contribution of rs35767 polymorphism 
to normochromic and normocytic anemia, we carried 
out a logistic regression analysis in a model which also 
included confounder factors affecting Hb concentration 
such as gender, and age. As compared with carriers of 
the TT genotype, those carrying the CC genotype had a 
2.4-fold higher risk of having anemia (OR 2.40, 95%CI 
1.19-4.82), while those carrying the CT genotype had a 
2.0-fold higher risk (OR 2.06, 95%CI 1.04-4.11). The 
association remained significant when fasting insulin 
levels were added to the model (Table 3), or when eGFR, 
smoking status, diagnosis of diabetes, treatment with 
ACE inhibitors, ARBs or diuretics, use of metformin and 
pioglitazone in diabetic patients were added to the model 
(Table 3), although its independence was not retained 
with the further inclusion into the model of fibrinogen and 
erythrocytes sedimentation rate (ESR) values (Table 3).
DISCUSSION
There is evidence from cell biology [12-16] and 
observational studies [17-20] suggesting that IGF-1 may 
have an important role in erythropoiesis [1-6]. Previous 
studies have repeatedly reported that the rs35767 
polymorphism near the IGF1 gene is associated with 
serum IGF-1 levels [23-28]. 
These observations coupled with the accessibility of 
a carefully characterized cohort of individuals of European 
ancestry have provided the rationale for addressing the 
question of whether the rs35767 polymorphism near 
IGF1 could be associated with haemoglobin concentration 
and anemia. We found that, individuals carrying the TT 
genotype, which is associated with higher circulating 
IGF-1 levels [23-28], exhibited significantly higher 
levels of haemoglobin concentration, and lower risk 
of having anemia as compared with carriers of the CT 
or CC genotype. The association between the rs35767 
polymorphism near IGF1 and anemia was not affected 
by other confounding factors such as gender, age, 
smoking status, glomerular filtration rate, diagnosis of 
type 2 diabetes, treatment with ACE inhibitors, ARBs or 
diuretics, use of metformin and pioglitazone in diabetic 
patients. The present data, coupled with the findings of 
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Table 1: Clinical characteristics of 3286 study subjects according to the SNP rs35767 near IGF1
Variables CC CT TT P P(T/T vs. C/C + C/T)
Male/Female 1088/1026 513/510 78/71 0.74 0.75
Age (yrs.) 52±13 52±14 54±10 0.22 0.22
BMI (kg/m2) 30.0±6.1 29.9±6.2 29.9±5.3 0.86 0.82
Waist circumference (cm) 101±14 101±15 102±14 0.77 0.17
Current smokers (%) 20.3 20.3 15.3 0.20 0.07
Systolic blood pressure (mmHg) 134±18 134±18 134±18 0.94 0.74
Diastolic blood pressure (mmHg) 81±11 81±11 81±10 0.85 0.80
Total cholesterol (mg/dl) 200±41 195±42 202±35 0.004 0.27
HDL (mg/dl) 50±14 50±14 50±14 0.76 0.90
Triglycerides (mg/dl) 136±78 134±94 137±83 0.39 0.68
HbA1c (%) [mmol/mol] 6.1±1.3 [43]
6.1±1.4 
[43]
6.2±1.3 
[44] 0.76 0.55
Fasting glucose (mg/dl) 100±45 110±44 111±38 0.95 0.77
Fasting insulin (µU/ml) 14±10 14±9 12±6 0.16 0.05
HOMA-IR 3.9±4.1 3.8±3.5 3.4±2.3 0.36 0.15
hsCRP (mg/l) 2.9±1.8 2.8±2.2 2.7±1.9 0.24 0.30
Fibrinogen (mg/dl) 326±83 328±87 310±72 0.07 0.02
Erythrocyte sedimentation rate  (mm/h) 11±9 11±9 8±6 0.08 0.02
eGFR (ml/min/1.73m2) 117±38 118±40 115±32 0.55 0.38
ACE inhibitor therapy, No.(%) 559 (32.4) 278 (33.5) 49 (38.9) 0.31 0.15
Angiotensin receptor blocker therapy, No.(%) 389 (18.4) 193 (18.9) 23 (15.4) 0.60 0.36
Diuretics, No.(%) 500 (23.7) 238 (23.3) 33 (22.1) 0.89 0.69
Patients with type 2 diabetes, No.(%) 547 (25.9) 277 (27.1) 46 (30.9) 0.35 0.21
Patients with type 2 diabetes treated with 
metformin and/or pioglitazone, No.(%) 186 (8.8) 110 (10.7) 14 (9.3) 0.21 0.88
Data are as means ± SD. Triglycerides, hsCRP, ESR, fasting insulin concentrations, and HOMA-IR were log transformed for 
statistical analysis, but values in the table represent a back transformation to the original scale. Categorical variables were 
compared by χ2 test. Unpaired Student’s t test or ANOVA were used to compare differences of continuous variables between 
the genotypes, as appropriate. BMI: body mass index; HDL: high density lipoprotein; eGFR: estimated glomerular filtration 
rate; hsCRP: high sensitivity C reactive protein; HOMA-IR: homeostasis model assessment index of insulin resistance.
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Table 2: Haematological characteristics of 3286 study subjects according to the SNP rs35767 near IGF1
Variables CC CT TT P P(T/T vs. C/C + C/T)
Hemoglobin (g/dl) 13.9±1.5 13.8±4.5 14.2±1.3 0.02 0.03
Hematocrit (%) 41±4.5 41±4.5 42±4.0 0.24 0.30
Mean corpuscular volume (fl) 85±9 85±8 85±5 0.81 0.88
Mean corpuscular hemoglobin (pg) 28.5±3.2 29.9±6.2 29.9±5.3 0.28 0.24
Serum Iron (μg/dl) 84±34 80±28 86±29 0.32 0.66
Subjects with anemia, No. (%) 244 (62.9%) 135 (35.0%) 9 (2.3%) 0.03 0.02
Data are means ± SD. Categorical variables were compared by χ2 test. Comparisons between the groups were performed using 
a general linear model.  P values refer to results after analyses with adjustment for age, and gender.
Table 3: Odds ratios (95% CI) by multiple logistic regression models for 
anemia in relation to the SNP rs35767 near IGF1
Anemia
Study groups OR  95%CI P 
Model 1
TT genotype (reference category) 1 --- ---
CC genotype 2.40 1.19–4.82 0.01
CT genotype 2.06 1.04–4.11 0.03
Model 2
TT genotype (reference category) 1 --- ---
CC genotype 2.86 1.22–6.68 0.01
CT genotype 2.33 1.02–5.39 0.04
Model 3
TT genotype (reference category) 1 --- ---
CC genotype 2.91 1.24–6.83 0.01
CT genotype 2.40 1.03–5.55 0.04
Model 4
TT genotype (reference category) 1 --- ---
CC genotype 3.21 0.98–10.60 0.055
CT genotype 2.48 0.77–8.11 0.13
Model 1: adjusted for age, and gender. Model 2: Model 1 + fasting insulin levels. Model 3: Model 
2 + eGFR, smoking status, diagnosis of diabetes, treatment with ACE inhibitors, ARBs or diuretics 
, use of metformin and pioglitazone in diabetic patients. Model 4: Model 3 + fibrinogen and ESR.
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previous observational studies showing an association 
between low IGF-1 concentration and anemia, support 
the idea that IGF-1 could be an important regulator 
of hemoglobin concentration in adults. In spite of the 
elevated interindividual variability of circulating IGF-
1 levels in adults, twin studies have indicated that 38% 
of the variance in IGF-1 concentration is attributable to 
genetic effects [30], suggesting the presence of a strong 
genetic determinant. In the Caucasian population, IGF-1 
promoters containing rs35767 C allele have been shown to 
possess a significantly higher transcriptional activity than 
T allele carriers, in both in vitro and case-control studies 
[27,28,31]. 
In humans a role for IGF-1 similar to that of 
hematopoietic cytokines has been proposed (extensively 
discussed in Maggio M, et al. 2015 [32]); observational 
studies have identified IGF-1 as cause of a wide range 
of anemic disorders; experimental and animal studies, 
have demonstrated the positive influence of IGF-1 on 
erythropoiesis and its involvement in various steps of 
the hematopoietic process. Mechanistically, a decrease 
in IGF-1 levels may affect hemoglobin concentration 
by reducing erythropoiesis as a consequence of 
diminished IGF-1-stimulated erythroid cell growth and 
differentiation from bone marrow or peripheral blood [13-
16]. Alternatively, because the rs35767 polymorphism 
near IGF1 has been shown to influence fasting insulin 
in genome-wide association studies [29], and insulin 
stimulates the proliferation of erythroid progenitor cells 
and mature erythroid progenitor cells through its own 
receptors [16], and, possibly, via insulin/IGF-1 hybrid 
receptors [16-29,33-37], it is possible to speculate that the 
effects of rs35767 polymorphism are mediated by insulin. 
Nevertheless, our findings that the association between 
rs35767 and anemia remained significant when fasting 
insulin levels were added to the model argue against this 
possibility. Instead, it is plausible that because IGF-1 
decreases the expression of inflammatory molecules and 
has anti-inflammatory effects [36], a decrease in IGF-1 
levels may result in higher concentrations of inflammatory 
proteins, which affect erythropoietin secretion, and red 
cell precursors survival [24]. Interestingly, we found 
that fibrinogen and ESR values were significantly 
lower in carriers of the TT genotype as compared with 
subjects carrying the C allele, and, more importantly, the 
inclusion of fibrinogen and ESR values in the logistic 
regression model containing all potential confounder 
factors, attenuated the risk for anemia of carriers of the TT 
genotype. Thus, an increase of anti-inflammatory action of 
IGF-1 may account for the lower risk of anemia observed 
in subjects carrying the TT genotype. 
The present study has several strengths, including 
the large sample size encompassing men and women, 
the demographically homogeneous group of Italians of 
European ancestry, the detailed clinical characterization 
that allowed us to adjust for multiple confounders, the 
exclusion of confounding chronic conditions potentially 
affecting both hemoglobin concentration and inflammatory 
biomarkers, the clinical and laboratory variables collected 
by a trained staff in a standardized manner, and the 
centralization of laboratory analyses. 
Nevertheless, some limitations should be considered 
in the interpretation of the current results. First, we 
employed the definition of anemia according to the WHO 
criteria [34] although other cutoffs for Hb concentration to 
define anemia have been proposed [38-40]. We opted for 
this definition since it has been widely used in previous 
studies thus making our results comparable to those 
previously reported [17-20]. A second limitation is that 
all variables, including circulating Hb concentration, were 
measured once. Although such an approach is common in 
clinical research, intra-individual variation in laboratory 
variables cannot be taken into account. Furthermore 
measurements of circulating IGF-1 levels were only 
available for a subgroup of subjects of the study cohort, 
thus we could not include them in our analyses. Another 
limitation of the present study is the cross-sectional 
design, making causal interpretations of associations 
between the rs35767 polymorphism near IGF1 and 
anemia risk difficult. In addition, to avoid an unpredictable 
modification of the characteristics of the original sample, 
we chose not to exclude the individuals treated with 
anti-hypertensive or glucose-lowering therapies, which 
may influence Hb concentration. However, correction 
of our analyses for medication intake did not affect the 
results. Although the present findings are clinically and 
biologically plausible, a further limitation of this study 
is represented by the robustness of our P values, which 
do not reach a genome-wide level of significance and are, 
therefore, still compatible with a false-positive result. 
Unfortunately the rs35767 polymorphism was not among 
the SNPs examined by the recently published GWAS on 
hemoglobin or hemoglobin-related traits, and no other 
SNPs among those tested, can function as a good proxy 
for it, thus data from genome-wide association studies 
could not be employed to replicate the associations 
reported. Additionally, the present results are based on 
adult individuals of European ancestry, and should not 
be extrapolated to other ethnic groups due to differences 
in socio-demographic, lifestyle, anthropometric, and 
genetic characteristics. Furthermore, our study cohort is 
recruited at a referral university hospital, representing 
subjects carrying at least one cardio-metabolic risk factor, 
and, therefore, the current findings may not be extendible 
to the healthy general population. Overall, the present 
results should be considered hypothesis generating and 
requiring confirmation by further prospective studies 
on well-characterized individuals of different ethnic 
groups. Nonetheless, we consider our results important 
in attempting to understand the pathophysiological 
interaction between the rs35767 polymorphism near IGF1 
and Hb concentration.
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MATERIALS AND METHODS
Study subjects 
The study group comprised 3286 individuals 
consecutively recruited at the Department of Systems 
Medicine of the University of Rome-Tor Vergata and 
at the Department of Medical and Surgical Sciences of 
the University “Magna Graecia” of Catanzaro [19,28]. 
The inclusion criteria were: the presence of one or more 
cardio-metabolic risk factors including family history of 
diabetes, dysglycemia/diabetes mellitus, hypertension, 
dyslipidemia, and overweight/obesity. Exclusion criteria 
comprised: history of type 1 diabetes mellitus, history 
of any malignant disease, end stage renal disease, heart 
failure, gastrointestinal affections associated with bleeding 
or malabsorption, macrocytic or microcytic anemia, 
hemoglobinopathies, hemolytic disease, autoimmune 
diseases, acute or chronic infections, acute or chronic 
pancreatitis, accumulation diseases such as amyloidosis 
and hemochromatosis, history of drug abuse, self-reporting 
alcohol consumption of >20 g⁄day, positivity for antibodies 
to hepatitis C virus (HCV) or hepatitis B surface antigen 
(HBsAg), and corticosteroids use. 
After a 12-h fasting, all individuals underwent 
anthropometrical evaluation including measurements 
of BMI, waist circumference, readings of clinic blood 
pressure; a venous blood sample was drawn for laboratory 
determinations. The study was approved by Institutional 
Ethics Committees of the University of Catanzaro and 
Rome Tor Vergata, and written informed consent was 
obtained from each participant before commencing 
the studies in accordance with the principles of the 
Declaration of Helsinki.
Analytical determinations
Haemoglobin, mean corpuscular haemoglobin 
(MCH), and mean corpuscular volume (MCV) were 
determined using an automated particle counter (Siemens 
Healthcare Diagnostics ADVIA® 120/2120 Haematology 
System, Milan, Italy). Glucose, triglycerides, total and 
high density lipoprotein (HDL) cholesterol concentrations 
were determined by enzymatic methods (Roche, 
Basel, Switzerland). HbA1c was measured with high 
performance liquid chromatography using a National 
Glycohemoglobin Standardization Program (NGSP) 
certified automated analyzer (Adams HA-8160 HbA1C 
analyzer, Menarini, Italy). High sensitivity C reactive 
protein (hsCRP) levels were assessed by an automated 
instrument (CardioPhase® hsCRP, Milan, Italy). Serum 
creatinine was measured by a clinical chemistry analyzer 
(Roche/Hitachi Modular Analytics System, P Module) 
using the Roche Creatinine Plus assay (Hoffman-La 
Roche, Basel, Switzerland). Erythrocyte sedimentation 
rate (ESR) was measured automatically by the stopped-
flow technique in a capillary microphotometer (Alifax Test 
1 System Polverara, Italy). Plasma insulin concentration 
was measured with a chemiluminescence-based assay 
(Immulite®, Siemens Healthcare GmbH, Erlangen, 
Germany).
DNA analysis
DNA was isolated from whole blood using a 
commercial DNA isolation kit (Promega, Madison, WI). 
Screening of rs35767 polymorphism was performed 
using a TaqMan allelic discrimination assay (Applied 
Biosystems, Foster City, CA). TaqMan genotyping 
reaction was amplified on the iCycler Thermal Cycler 
and fluorescence was detected using the embedded iQ5 
Multicolor Real-Time PCR Detection System (Bio-Rad 
Laboratories, Inc., Hercules, CA). Genotyping quality 
was tested by including 3 HapMap samples in each 96-
well plate. The agreement rate with the HapMap database 
genotypes was >99%. 
Calculations
Anemia was defined according to the World Health 
Organization (WHO) criteria as hemoglobin <12 g/dl in 
women and <13 g/dl in men [34]. The homeostasis model 
assessment index of insulin resistance (HOMA-IR) was 
calculated as fasting insulin × fasting glucose/22.5 [33]. 
Estimated glomerular filtration rate (eGFR) was calculated 
by using the CKD-EPI equation [35]: eGFR = 141 x 
min(Scr/k, 1)α x max(Scr/k, 1)-1.209 x 0.993Age x 1.018 [if 
female], where Scr is serum creatinine, k is 0.7 for females 
and 0.9 for males, α is -0.329 for females and -0.411 for 
males, min indicates the minimum of Scr/k or 1, and max 
indicates the maximum of Scr/k or 1).
Statistical analysis
Due to a skewed distribution, triglycerides, 
high sensitivity C-reactive protein (hsCRP), ESR, 
fasting insulin concentrations, and HOMA-IR were 
natural log transformed for statistical analyses. The 
results for continuous variables are given as means 
± SD. Categorical variables were compared by χ2-
test. Unpaired Student’s t test or ANOVA were used to 
compare differences of continuous variables between the 
genotypes, as appropriate. Differences of haematological 
variables between groups were tested after adjusting for 
confounding factors such as age, and gender by ANCOVA 
(general linear model). The Hardy-Weinberg equilibrium 
between the genotypes was evaluated by χ2 test. Genotype 
distributions were in Hardy-Weinberg equilibrium 
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(P>0.05). The study had 80% power (for α=0.05) to detect 
a 2-fold or greater OR for anemia according to a recessive 
model. A logistic regression analysis was used to model 
the effect of rs35767 polymorphism on anemia and results 
were reported as odds ratios (ORs) with 95% CIs. Two-
sided P value <0.05 was considered statistically significant 
given the high prior probabilities for association of the 
rs35767 polymorphism with the examined traits (the 
locus has already been repeatedly associated with IGF-1 
levels [23-28]). All analyses were performed using SPSS 
(Chicago, IL, USA) software programme Version 22.0 for 
Windows.
Abbreviations
EPO: erythropoietin; ACE: angiotensin-converting 
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